Clinical Trials on Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Total 18 results
-
AstraZenecaISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALITerminatedPatients With Advanced Ovarian Cancer Sensitive to Platinum-based ChemotherapyItaly, Germany
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
AstraZenecaActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum SensitiveChina, Malaysia
-
Hadassah Medical OrganizationUnknownFemale Patients Aged 5-35 Prior to Systemic Chemotherapy | With Significant Risk of Ovarian ToxicityIsrael
-
TILT Biotherapeutics Ltd.Merck Sharp & Dohme LLCRecruitingPlatinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditionsUnited States, Finland
-
Rhizen Pharmaceuticals SAActive, not recruitingSolid Tumor | Metastatic Breast Cancer | Locally Advanced Breast Cancer | Extensive-stage Small-cell Lung Cancer | Platinum-Sensitive Fallopian Tube Carcinoma | Platinum-sensitive Ovarian Cancer | Platinum-Sensitive Peritoneal CancerCzechia, Poland
-
Yonsei UniversityTakedaRecruitingPlatinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorKorea, Republic of
-
Hospices Civils de LyonRecruitingAdult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian CancerFrance
-
CHU de ReimsCompletedPatients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based ChemotherapyFrance
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPatients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) RiskChina
-
Astellas Pharma IncCompletedNon-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyUnited Kingdom, United States, Brazil, Canada, Germany, Korea, Republic of, Poland, Romania, Russian Federation
-
Aprea TherapeuticsCompletedPlatinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
-
AstraZenecaMerck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.Active, not recruitingAdvanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum ChemotherapyKorea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
-
Philogen S.p.A.TerminatedPancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical ResectionItaly, Germany
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma and other conditionsUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingPremenopausal Breast Cancer | Hormone-receptor-positive Breast Cancer | Breast Cancer Patients at Intermediate to High Risk | Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or TorimefenChina
-
AstraZenecaNot yet recruitingUsing NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE
-
Fujian Cancer HospitalNot yet recruitingNon-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions